175 related articles for article (PubMed ID: 36120913)
1. A patent and literature review of CDK12 inhibitors.
Tang R; Liu J; Li S; Zhang J; Yu C; Liu H; Chen F; Lv L; Zhang Q; Yuan K; Shao H
Expert Opin Ther Pat; 2022 Oct; 32(10):1055-1065. PubMed ID: 36120913
[TBL] [Abstract][Full Text] [Related]
2. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
[TBL] [Abstract][Full Text] [Related]
3. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
4. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
Blazek D; Kohoutek J; Bartholomeeusen K; Johansen E; Hulinkova P; Luo Z; Cimermancic P; Ule J; Peterlin BM
Genes Dev; 2011 Oct; 25(20):2158-72. PubMed ID: 22012619
[TBL] [Abstract][Full Text] [Related]
5. Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
Choi SH; Kim S; Jones KA
Exp Mol Med; 2020 May; 52(5):762-771. PubMed ID: 32451425
[TBL] [Abstract][Full Text] [Related]
6. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
Kovalová M; Baraka JP; Mik V; Jorda R; Luo L; Shao H; Kryštof V
Expert Opin Ther Pat; 2023 Feb; 33(2):67-87. PubMed ID: 36975020
[TBL] [Abstract][Full Text] [Related]
7. Current progress and novel strategies that target CDK12 for drug discovery.
Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
[TBL] [Abstract][Full Text] [Related]
8. Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II.
Cheng SW; Kuzyk MA; Moradian A; Ichu TA; Chang VC; Tien JF; Vollett SE; Griffith M; Marra MA; Morin GB
Mol Cell Biol; 2012 Nov; 32(22):4691-704. PubMed ID: 22988298
[TBL] [Abstract][Full Text] [Related]
9.
Liang S; Hu L; Wu Z; Chen Z; Liu S; Xu X; Qian A
Cells; 2020 Jun; 9(6):. PubMed ID: 32570740
[TBL] [Abstract][Full Text] [Related]
10. Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy.
Wu W; Yu S; Yu X
Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188842. PubMed ID: 36460141
[TBL] [Abstract][Full Text] [Related]
11. CDK12: a potential therapeutic target in cancer.
Emadi F; Teo T; Rahaman MH; Wang S
Drug Discov Today; 2020 Dec; 25(12):2257-2267. PubMed ID: 33038524
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation.
Chen HH; Wang YC; Fann MJ
Mol Cell Biol; 2006 Apr; 26(7):2736-45. PubMed ID: 16537916
[TBL] [Abstract][Full Text] [Related]
13. Discovery and resistance mechanism of a selective CDK12 degrader.
Jiang B; Gao Y; Che J; Lu W; Kaltheuner IH; Dries R; Kalocsay M; Berberich MJ; Jiang J; You I; Kwiatkowski N; Riching KM; Daniels DL; Sorger PK; Geyer M; Zhang T; Gray NS
Nat Chem Biol; 2021 Jun; 17(6):675-683. PubMed ID: 33753926
[TBL] [Abstract][Full Text] [Related]
14. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract][Full Text] [Related]
15. Role and therapeutic potential of CDK12 in human cancers.
Chilà R; Guffanti F; Damia G
Cancer Treat Rev; 2016 Nov; 50():83-88. PubMed ID: 27662623
[TBL] [Abstract][Full Text] [Related]
16. CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model.
Ketley A; Wojciechowska M; Ghidelli-Disse S; Bamborough P; Ghosh TK; Morato ML; Sedehizadeh S; Malik NA; Tang Z; Powalowska P; Tanner M; Billeter-Clark R; Trueman RC; Geiszler PC; Agostini A; Othman O; Bösche M; Bantscheff M; Rüdiger M; Mossakowska DE; Drewry DH; Zuercher WJ; Thornton CA; Drewes G; Uings I; Hayes CJ; Brook JD
Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350131
[TBL] [Abstract][Full Text] [Related]
17. CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signaling.
Henry KL; Kellner D; Bajrami B; Anderson JE; Beyna M; Bhisetti G; Cameron T; Capacci AG; Bertolotti-Ciarlet A; Feng J; Gao B; Hopkins B; Jenkins T; Li K; May-Dracka T; Murugan P; Wei R; Zeng W; Allaire N; Buckler A; Loh C; Juhasz P; Lucas B; Ennis KA; Vollman E; Cahir-McFarland E; Hett EC; Ols ML
Sci Signal; 2018 Jul; 11(541):. PubMed ID: 30065029
[TBL] [Abstract][Full Text] [Related]
18. CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability.
Choi SH; Martinez TF; Kim S; Donaldson C; Shokhirev MN; Saghatelian A; Jones KA
Genes Dev; 2019 Apr; 33(7-8):418-435. PubMed ID: 30819820
[TBL] [Abstract][Full Text] [Related]
19. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
Dubbury SJ; Boutz PL; Sharp PA
Nature; 2018 Dec; 564(7734):141-145. PubMed ID: 30487607
[TBL] [Abstract][Full Text] [Related]
20. Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers.
Wen T; Wang J; Lu R; Tan S; Li P; Yao X; Liu H; Yi Z; Li L; Liu S; Gao P; Qian H; Xie G; Ma F
Eur J Med Chem; 2023 Mar; 250():115199. PubMed ID: 36827953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
